key: cord-0942690-i6aook9q
authors: Dinnes, Jacqueline; Deeks, Jonathan J; Adriano, Ada; Berhane, Sarah; Davenport, Clare; Dittrich, Sabine; Emperador, Devy; Takwoingi, Yemisi; Cunningham, Jane; Beese, Sophie; Dretzke, Janine; Ferrante di Ruffano, Lavinia; Harris, Isobel M; Price, Malcolm J; Taylor-Phillips, Sian; Hooft, Lotty; Leeflang, Mariska MG; Spijker, René; Van den Bruel, Ann
title: Rapid, point‐of‐care antigen and molecular‐based tests for diagnosis of SARS‐CoV‐2 infection
date: 2020-08-26
journal: Cochrane Database Syst Rev
DOI: 10.1002/14651858.cd013705
sha: db5d574d9ba6855faf05b269a208eb4b50853306
doc_id: 942690
cord_uid: i6aook9q

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and the resulting COVID‐19 pandemic present important diagnostic challenges. Several diagnostic strategies are available to identify or rule out current infection, identify people in need of care escalation, or to test for past infection and immune response. Point‐of‐care antigen and molecular tests to detect current SARS‐CoV‐2 infection have the potential to allow earlier detection and isolation of confirmed cases compared to laboratory‐based diagnostic methods, with the aim of reducing household and community transmission. OBJECTIVES: To assess the diagnostic accuracy of point‐of‐care antigen and molecular‐based tests to determine if a person presenting in the community or in primary or secondary care has current SARS‐CoV‐2 infection. SEARCH METHODS: On 25 May 2020 we undertook electronic searches in the Cochrane COVID‐19 Study Register and the COVID‐19 Living Evidence Database from the University of Bern, which is updated daily with published articles from PubMed and Embase and with preprints from medRxiv and bioRxiv. In addition, we checked repositories of COVID‐19 publications. We did not apply any language restrictions. SELECTION CRITERIA: We included studies of people with suspected current SARS‐CoV‐2 infection, known to have, or not to have SARS‐CoV‐2 infection, or where tests were used to screen for infection. We included test accuracy studies of any design that evaluated antigen or molecular tests suitable for a point‐of‐care setting (minimal equipment, sample preparation, and biosafety requirements, with results available within two hours of sample collection). We included all reference standards to define the presence or absence of SARS‐CoV‐2 (including reverse transcription polymerase chain reaction (RT‐PCR) tests and established clinical diagnostic criteria). DATA COLLECTION AND ANALYSIS: Two review authors independently screened studies and resolved any disagreements by discussion with a third review author. One review author independently extracted study characteristics, which were checked by a second review author. Two review authors independently extracted 2x2 contingency table data and assessed risk of bias and applicability of the studies using the QUADAS‐2 tool. We present sensitivity and specificity, with 95% confidence intervals (CIs), for each test using paired forest plots. We pooled data using the bivariate hierarchical model separately for antigen and molecular‐based tests, with simplifications when few studies were available. We tabulated available data by test manufacturer. MAIN RESULTS: We included 22 publications reporting on a total of 18 study cohorts with 3198 unique samples, of which 1775 had confirmed SARS‐CoV‐2 infection. Ten studies took place in North America, two in South America, four in Europe, one in China and one was conducted internationally. We identified data for eight commercial tests (four antigen and four molecular) and one in‐house antigen test. Five of the studies included were only available as preprints. We did not find any studies at low risk of bias for all quality domains and had concerns about applicability of results across all studies. We judged patient selection to be at high risk of bias in 50% of the studies because of deliberate over‐sampling of samples with confirmed COVID‐19 infection and unclear in seven out of 18 studies because of poor reporting. Sixteen (89%) studies used only a single, negative RT‐PCR to confirm the absence of COVID‐19 infection, risking missing infection. There was a lack of information on blinding of index test (n = 11), and around participant exclusions from analyses (n = 10). We did not observe differences in methodological quality between antigen and molecular test evaluations. Antigen tests Sensitivity varied considerably across studies (from 0% to 94%): the average sensitivity was 56.2% (95% CI 29.5 to 79.8%) and average specificity was 99.5% (95% CI 98.1% to 99.9%; based on 8 evaluations in 5 studies on 943 samples). Data for individual antigen tests were limited with no more than two studies for any test. Rapid molecular assays Sensitivity showed less variation compared to antigen tests (from 68% to 100%), average sensitivity was 95.2% (95% CI 86.7% to 98.3%) and specificity 98.9% (95% CI 97.3% to 99.5%) based on 13 evaluations in 11 studies of on 2255 samples. Predicted values based on a hypothetical cohort of 1000 people with suspected COVID‐19 infection (with a prevalence of 10%) result in 105 positive test results including 10 false positives (positive predictive value 90%), and 895 negative results including 5 false negatives (negative predictive value 99%). Individual tests We calculated pooled results of individual tests for ID NOW (Abbott Laboratories) (5 evaluations) and Xpert Xpress (Cepheid Inc) (6 evaluations). Summary sensitivity for the Xpert Xpress assay (99.4%, 95% CI 98.0% to 99.8%) was 22.6 (95% CI 18.8 to 26.3) percentage points higher than that of ID NOW (76.8%, (95% CI 72.9% to 80.3%), whilst the specificity of Xpert Xpress (96.8%, 95% CI 90.6% to 99.0%) was marginally lower than ID NOW (99.6%, 95% CI 98.4% to 99.9%; a difference of −2.8% (95% CI −6.4 to 0.8)) AUTHORS' CONCLUSIONS: This review identifies early‐stage evaluations of point‐of‐care tests for detecting SARS‐CoV‐2 infection, largely based on remnant laboratory samples. The findings currently have limited applicability, as we are uncertain whether tests will perform in the same way in clinical practice, and according to symptoms of COVID‐19, duration of symptoms, or in asymptomatic people. Rapid tests have the potential to be used to inform triage of RT‐PCR use, allowing earlier detection of those testing positive, but the evidence currently is not strong enough to determine how useful they are in clinical practice. Prospective and comparative evaluations of rapid tests for COVID‐19 infection in clinically relevant settings are urgently needed. Studies should recruit consecutive series of eligible participants, including both those presenting for testing due to symptoms and asymptomatic people who may have come into contact with confirmed cases. Studies should clearly describe symptomatic status and document time from symptom onset or time since exposure. Point‐of‐care tests must be conducted on samples according to manufacturer instructions for use and be conducted at the point of care. Any future research study report should conform to the Standards for Reporting of Diagnostic Accuracy (STARD) guideline.

Any rapid antigen or molecular-based test for diagnosis of SARS-CoV-2 meeting the following criteria:

• portable or mains-powered device • minimal sample preparation requirements • minimal biosafety requirements • no requirement for a temperature-controlled environment • test results available within 2 hours of sample collection

For COVID-19 cases: positive RT-PCR alone or clinical diagnosis of COVID-19 based on established guidelines or combinations of clinical features

For non-COVID-19 cases: repeated negative RT-PCR or pre-pandemic sources of samples Action False negative results mean missed cases of COVID-19 infection, with either delayed or no confirmed diagnosis and increased risk of community transmission due to false sense of security False positive results lead to unnecessary self-isolation or quarantine, with the potential for new infection to be acquired Cochrane Database of Systematic Reviews

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting COVID-19 pandemic present important diagnostic evaluation challenges. These range from: understanding the value of signs and symptoms in predicting possible infection; assessing whether existing biochemical and imaging tests can identify infection or people needing critical care; and evaluating whether new biomarker tests can accurately identify current infection, rule out infection, identify people in need of care escalation, or test for past infection and immunity.

We are creating and maintaining a suite of living systematic reviews to cover the roles of tests and patient characteristics in the diagnosis of COVID-19. This review summarises evidence for the accuracy of rapid antigen and molecular tests, suitable for use at the point of care, as alternatives to standard laboratory-based reverse transcription polymerase chain reaction (RT-PCR), that are relied on for identifying current infection. If su iciently accurate, point-of-care tests may have a greater impact on public health than RT-PCR as they do not require the same technical expertise and laboratory capacity. These tests can be undertaken locally, avoiding the need for centralised testing facilities that rarely meet the needs of patients, caregivers, health workers and society as a whole, especially in low-and middle-income countries. As these are rapid tests, their results can be returned within the same clinical encounter, facilitating timely decisions concerning the need for isolation.

COVID-19 is the disease caused by infection with the SARS-CoV-2 virus. The key target conditions for this suite of reviews are current SARS-CoV-2 infection, current COVID-19 disease, and past SARS-CoV-2 infection. The tests included in this review concern the identification of current infection.

For current infection, the severity of the disease is of importance. SARS-CoV-2 infection can be asymptomatic (no symptoms); mild or moderate (symptoms such as fever, cough, aches, lethargy but without di iculty breathing at rest); severe (symptoms with breathlessness and increased respiratory rate indicative of pneumonia); or critical (requiring respiratory support due to severe acute respiratory syndrome (SARS) or acute respiratory distress syndrome (ARDS). People with COVID-19 pneumonia (severe or critical disease) require di erent patient management, and it is important to be able to identify them. Viral load may also be an indicator of disease severity (Zheng 2020), and whilst the accuracy of antigen and molecular tests have the potential to be a ected by participant viral load, the main aim of rapid testing is not to establish viral load. In this review, we therefore consider the role of point-of-care tests for detecting SARS-CoV-2 infection of any severity.

The primary consideration for the eligibility of tests for inclusion in this review is that they should detect current infection and should have the capacity to be performed at the 'point of care' or in a 'nearpatient' testing role. There is an ongoing debate around the specific use and definitions of these terms, therefore for the purposes of this review, we consider 'point-of-care' and 'near patient' to be synonymous, but for consistency and avoidance of confusion, we use the term 'point-of-care' throughout.

We have adapted a definition of point-of-care testing, namely that it "refers to decentralized testing that is performed by a minimally trained healthcare professional near a patient and outside of central laboratory testing" (WHO 2018) , with the additional caveat that test results must be available within a single clinical encounter (Pai 2012). The key criteria for test inclusion are therefore:

• the equipment for running and or reading the assay must be portable or easily transported, although mains power may be required; • minimal sample preparation requirements, for example, singlestep mixing, with no requirement for additional equipment or precise sample volume transfer unless a disposable automatic fill or graduated transfer device is used; • minimal biosafety requirements, for example, personal protective equipment (PPE) for sample collector and test operator, good ventilation and a biohazard bag for waste disposal; • no requirement for a temperature-controlled environment; and • test results available within two hours of sample collection.

Tests for detection of current infection that are currently suitable for use at the point of care include antigen tests and molecularbased tests. Both types of test use the same respiratory-tract samples acquired by swabbing, washing or aspiration as for laboratory-based RT-PCR. Rapid antigen tests use lateral flow immunoassays, which are disposable devices, usually in the form of plastic cassettes akin to a pregnancy test. Viral antigen is captured by dedicated antibodies that are either colloidal gold-or fluorescent-labelled. Antigen detection is indicated by visible lines appearing on the test strip (colloidal gold-based immunoassays, or CGIA), or through fluorescence, which can be detected using an immunofluorescence analyser (fluorescence immunoassays or FIA). Molecular-based tests to detect viral ribonucleic acid (RNA) have historically been laboratory-based assays using RT-PCR technology (see Alternative test(s)). In recent years, automated, single-step RT-PCR methods have been developed, as well as other nucleic acid amplification methods, such as isothermal amplification, that do not require the sophisticated thermo cycling involved in RT-PCR (Carter 2020). These technological advances have allowed molecular technologies to be developed that are suitable for use in a point-of-care context (Kozel 2017).

Following the emergence of COVID-19 there has been prolific industry activity to develop accurate tests. The Foundation for Innovative Diagnostics (FIND) and Johns Hopkins Centre for Health Security have maintained online lists of these and other molecularbased tests for SARS-CoV-2 (FIND 2020). At the time of writing (19 July 2020), FIND listed 48 rapid antigen tests, 32 of which are described as "commercialized" and 21 have been identified as having regulatory approval. A total of 113 molecular tests were described as automated, including both laboratory-based assays and assays suitable for use outside of a laboratory setting (i.e. near or at the point of care). Further information from FIND indicates that 47 of the 113 assays were categorised as point-of-care or near point-of-care tests, including 26 with regulatory approval. This classification was based on the information provided to FIND by the test manufacturers and does not necessarily mean that these tests meet the criteria for point-of-care tests that we have specified for Library Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews this review. The numbers of tests of these types will increase over time.

Patients may be tested for infection when they present with symptoms, or have had known exposure to COVID-19, or during screening for COVID-19. The standard approach to diagnosis of COVID-19 infection is through laboratory-based testing of swab samples taken from the upper respiratory (e.g. nasopharynx, oropharynx) or lower respiratory tract (e.g. bronchoalveolar lavage or sputum) with RT-PCR. RT-PCR is the primary method for detecting infection during the acute phase of the illness while the virus is still present (whether people are symptomatic or asymptomatic), but can give false negative results (Arevalo-Rodriguez 2020). Both the World Health Organiation (WHO) and the China CDC (National Health Commission of the People's Republic of China), have produced case definitions for COVID-19 that include the presence of convincing clinical evidence when RT-PCR is negative (Appendix 1). The most recent case definition from the China CDC also includes positive serology tests.

Signs and symptoms are used in the initial diagnosis of suspected COVID-19 infection and to help identify those who require a test for RT-PCR. A number of key symptoms have been associated with mild to moderate COVID-19, including: troublesome dry cough (for example, coughing more than usual over a one-hour period, or three or more coughing episodes in 24 hours), fever greater than 37.8 °C, diarrhoea, headache, breathlessness on light exertion, muscle pain, fatigue, and loss of sense of smell and taste. However, the recently published review of signs and symptoms found good evidence for the accuracy for these symptoms alone or in combination to be lacking (Struyf 2020).

Where people are asymptomatic but are being tested on the basis of epidemiological risk factors, such as exposure to someone with confirmed SARS-CoV-2, no prior tests will have been conducted.

For most settings in which testing for acute SARS-CoV-2 infection takes place, results of laboratory-based RT-PCR tests are unlikely to be available within a single clinical encounter. Point-of-care tests potentially have a role either as a replacement for RT-PCR (if su iciently accurate), or as a means of triaging and rapid management (quarantine or treatment, or both), with confirmatory RT-PCR testing for negative results. Obtaining quick results within a healthcare visit will allow more appropriate decisions about isolation and healthcare interventions. If accurate, tests may also be considered for screening at-risk populations, for example in airport settings or in local outbreaks.

This review is one of seven planned reviews that cover the range of tests and characteristics being considered in the management of COVID-19 (Deeks 2020; McInnes 2020) . Full details of the alternative tests and evidence of their accuracy will be summarised in these reviews. Tests that might be considered as alternatives to point-ofcare tests are considered here.

RT-PCR tests for SARS-CoV-2 identify viral ribonucleic acid (RNA). Reagents for RT-PCR were rapidly produced once the viral RNA sequence was published (Corman 2020). Testing is undertaken in central laboratories and can be very labour-intensive, with several points along the path of performing a single test where errors may occur, although some automation of parts of the process is possible. The amplification process requires thermal cycling equipment to allow multiple temperature changes within a cycle, with cycles repeated up to 40 times until viral DNA is detected (Carter 2020). Although the amplification process for RT-PCR can be completed in a relatively short timeframe, the stages of extraction, sample processing and data management (including reporting) mean that test results are typically only available in 24 to 48 hours. Where testing is undertaken in a centralised laboratory, transport times increase this further. The time to result for fully automated RT-PCR assays is shorter than for manual RT-PCR, however most assays still require sample preparation steps that make them unsuitable for use at the point of care. Other nucleic acid amplification methods, including loop-mediated isothermal amplification (LAMP), or CRISPR-based nucleic acid detection methods, that allow amplification at a constant temperature are also being developed (Carter 2020). These methods have the potential to reduce the time to produce test results a er extraction and sample processing to minutes, but the time for the whole process may still be significant. Laboratory-based molecular tests are most o en applied to upper and lower respiratory samples although they are also being used on faecal and urine samples.

Serology tests to measure antibodies to SARS-CoV-2 have been evaluated in people with active infection and in convalescent cases (Deeks 2020a). Antibodies are formed by the body's immune system in response to infections, and can be detected in whole blood, plasma or serum. Antibody tests are available for laboratory use including enzyme-linked immunosorbent assay (ELISA) methods, or more advanced chemiluminescence immunoassays (CLIA). There are also rapid lateral flow assays (LFA)s for antibody testing that use a minimal amount of whole blood, plasma or serum on a testing strip as opposed to the respiratory specimens that are used for rapid antigen tests; all assays for antibody detection are considered in Deeks 2020a.

It is essential to understand the clinical accuracy of tests and diagnostic features to identify the best way they can be used in di erent settings to develop e ective diagnostic and management pathways. The suite of Cochrane 'living systematic reviews' summarises evidence on the clinical accuracy of di erent tests and diagnostic features, grouped according to the research questions and settings that we are aware of. Estimates of accuracy from these reviews will help inform diagnosis, screening, isolation, and patient-management decisions.

As the COVID-19 pandemic progresses, earlier, fast and reliable detection of active SARS-CoV-2 infection is key to reducing community transmission. New biomarker tests are being developed and evidence is accumulating at an unprecedented rate. Point-of-care testing provides a potentially attractive route to increasing testing rates; however their potential to have an impact on patient care and help reduce transmission depends not only on the time it takes to report the test result, but on test performance and frequency of testing. We are aware of two other reviews on this topic (Green 2020; Subsoontorn 2020). One rapid review of point-of-care tests relied on performance data from manufacturers' instructions for use documents (Green 2020). A systematic review of nucleic acid amplification 'point-of-care tests' selected studies for inclusion based on the use of isothermal techniques (i.e. not requiring thermal cycling), with apparently no consideration for the feasibility of deploying the tests in a point-of-care environment (Subsoontorn 2020). A comprehensive systematic review of the clinical performance of tests suitable for use at the point of care is therefore urgently needed. We will update this review as o en as is feasible to ensure that it provides current evidence about the accuracy of point-of-care tests.

Please note, this review follows a generic protocol that covers six of the seven Cochrane COVID-19 DTA reviews (Deeks 2020). The Background and Methods sections of this review therefore use some text that was originally published in the protocol (Deeks 2020), and text that overlaps some of our other reviews (Deeks 2020a; Struyf 2020).

To assess the diagnostic accuracy of rapid point-of-care antigen and molecular-based tests to determine if a person presenting in the community or in primary or secondary care has current SARS-CoV-2 infection.

Where data are available, we will investigate potential sources of heterogeneity that may influence diagnostic accuracy (either by stratified analysis or meta-regression) according to index test, participant characteristics (length and severity of symptoms, and viral load), study setting, study design and reference standard used.

We applied broad eligibility criteria in order to include all patient groups (that is, if patient population was unclear, we included the study) and all variations of a test.

We included studies of all designs that produce estimates of test accuracy or provide data from which we can compute estimates, including the following.

• Studies restricted to participants confirmed to either have (or to have had) the target condition (to estimate sensitivity) or confirmed not to have (or have had) the target condition (to estimate specificity). These types of studies may be excluded in later review updates. • Single-group studies, which recruit participants before disease status has been ascertained. • Multi-group studies, where people with and without the target condition are recruited separately (o en referred to as two-gate or diagnostic case-control studies). • Studies based on either patients or samples.

We excluded studies from which we could not extract data to compute either sensitivity or specificity.

We carefully considered the limitations of di erent study designs in the quality assessment and analyses.

We included studies reported in published articles and as preprints.

We included studies recruiting people presenting with suspicion of current SARS-CoV-2 infection or those recruiting populations where tests were used to screen for disease (for example, contact tracing or community screening).

We also included studies that recruited people known to have SARS-CoV-2 infection and known not to have SARS-CoV-2 infection (i.e. cases only or multi-group studies).

We excluded small studies with fewer than 10 samples or participants. Although the size threshold of 10 is arbitrary, such small studies are likely to give unreliable estimates of sensitivity or specificity and may be biased.

We included studies evaluating any rapid antigen or molecularbased test for diagnosis of SARS-CoV-2, if it met the criteria outlined in the Background, that is, requiring minimal equipment, sample preparation, and biosafety considerations, with results available within two hours of sample collection.

The target condition was current SARS-CoV-2 infection (either symptomatic or asymptomatic). We also refer to SARS-CoV-2 infection as 'COVID-19 infection'.

We anticipated that studies would use a range of reference standards to define both the presence and absence of SARS-CoV-2 infection but were unclear at the start of the review exactly what methods we would encounter. For the QUADAS-2 (Quality Assessment tool for Diagnostic Accuracy Studies; Whiting 2011), assessment we categorised each method of defining the presence of SARS-CoV-2 according to the risk of bias (the chances that it would misclassify the presence or absence of infection) and whether it defined COVID-19 in an appropriate way that reflected cases encountered in practice. Likewise, we considered the risk of bias in definitions of the absence of SARS-CoV-2, and whether the definition included all those who would be tested in practice.

Evaluations of molecular tests generally consider agreement between molecular assays, for example, agreement of a new rapid test against a more standard RT-PCR test. For the purposes of this review, we considered RT-PCR to be the 'reference standard' against which the rapid tests were compared, and present results as 'sensitivity' and 'specificity' as opposed to percentage agreement. The result of further RT-PCR analysis of discrepant cells (samples with results disagreeing on the rapid test and the RT-PCR) were also considered in sensitivity analyses. As discrepant analysis involves retesting only a subsample of patients selected according to index and reference standard results, it can introduce bias (Hadgu 1999 

We conducted a single literature search to cover our suite of Cochrane COVID-19 diagnostic test accuracy (DTA) reviews (Deeks 2020; McInnes 2020).

We conducted electronic searches using two primary sources. Both of these searches aimed to identify all published articles and preprints related to COVID-19, and were not restricted to those evaluating biomarkers or tests. Thus, there are no test terms, diagnosis terms, or methodological terms in the searches. Searches were limited to 2019 and 2020, and for this version of the review have been conducted to 25 May 2020. 

From 28 March 2020, we used the COVID-19 Living Evidence database from the Institute of Social and Preventive Medicine (ISPM) at the University of Bern (www.ispm.unibe.ch), as the primary source of records for the Cochrane COVID-19 DTA reviews. This search includes PubMed, Embase, and preprints indexed in bioRxiv and medRxiv databases. The strategies as described on the ISPM website are described here (ispmbern.github.io/covid-19/). See Appendix 3. To ensure comprehensive coverage we also downloaded records from the 'Bern feed' from 1 January to 28 March 2020 and de-duplicated them against those obtained via the Cochrane COVID-19 Study Register.

The decision to focus primarily on the Bern feed was because of the exceptionally large numbers of COVID-19 studies available only as preprints. The Cochrane COVID-19 Study Register has undergone a number of iterations since the end of March and we anticipate moving back to the Register as the primary source of records for subsequent review updates. We appeal to researchers to supply details of additional published or unpublished studies at the following email address, which we will consider for inclusion in future updates (coviddta@contacts.bham.ac.uk).

A team of experienced systematic review authors from the University of Birmingham screened the titles and abstracts of all records retrieved from the literature searches. Two review authors independently screened studies in Covidence. A third, senior review author resolved any disagreements. We tagged all records selected as potentially eligible according to the Cochrane COVID-19 DTA review(s) that they might be eligible for and we then exported them to separate Covidence reviews for each review title.

We obtained the full texts for all studies flagged as potentially eligible. Two review authors independently screened the full texts for one of the COVID-19 biomarker reviews (molecular, antigen or antibody tests). We resolved any disagreements on study inclusion through discussion with a third review author.

One review author extracted the characteristics of each study, which a second review author checked. Items that we extracted are listed in Appendix 5. In addition, we coded tests according to complexity, regardless of the nature of the test (antigen or molecular test), as follows:

• low: one sample preparation step and up to two test steps;

• moderate: two sample preparation steps and up to three test steps; • high: more than two sample preparation steps and more than three test steps.

Two review authors independently carried out this classification, with referral to a third review author if necessary.

Both review authors independently performed data extraction of 2x2 contingency tables of the number of true positives, false positives, false negatives and true negatives. They resolved disagreements by discussion. Where possible, we separately extracted data according to viral load, and for molecular assays, before and a er re-analysis of samples in discrepant cells.

We encourage study authors to contact us regarding missing details on the included studies (coviddta@contacts.bham.ac.uk).

Trusted evidence. Informed decisions. Better health.

Two review authors independently assessed risk of bias and applicability concerns using the QUADAS-2 checklist tailored to this review (Appendix 6; Whiting 2011). The two review authors resolved any disagreements by discussion.

Ideally, studies should prospectively recruit a representative sample of participants presenting with signs and symptoms of COVID-19, either in community or primary care settings or to a hospital setting, and they should clearly record the time of testing a er the onset of symptoms. Studies in asymptomatic people at risk of infection should document time from exposure. Studies should perform tests in their intended use setting, using appropriate samples with or without viral transport medium and within the time period following specimen collection as indicated in the 'instructions for use' document. 

We analysed rapid antigen and molecular tests separately. If studies evaluated multiple tests in the same samples, we included them multiple times. We present estimates of sensitivity and specificity for each test brand using paired forest plots, and summarise results using average sensitivity and specificity in tables as appropriate. There were only su icient studies to make formal comparisons (based on between-study comparisons) for studies using two brands of molecular tests (ID NOW (Abbott Laboratories) and Xpert Xpress (Cepheid Inc)).

We estimated summary sensitivities and specificities with 95% confidence intervals (CI) using the bivariate model (Reitsma 2005) , via the meqrlogit command of Stata/SE 16.0. When few studies were available, we simplified models by first assuming no correlation between sensitivity and specificity estimates and secondly by setting near-zero variance estimates of the random e ects to zero (Takwoingi 2017). In cases where there was only one study per test, we reported individual sensitivities and specificities with 95% CI constructed using the binomial exact method.

Where studies presented only estimates of sensitivity, we fitted univariate random e ects logistic regression models. In a small number of instances where a model failed to converge (usually when there were very small numbers of studies or the sensitivity/ specificity estimates were all very high), we computed estimates and CI by summing the counts of TP, FP, FN and TN across 2x2 tables. These analyses are clearly marked in the tables. We present all estimates with 95% confidence intervals.

We examined heterogeneity between studies by visually inspecting the forest plots of sensitivity and specificity. Where adequate data were available, we investigated heterogeneity related to viral load, test brand, and sample type by including indicator variables in the random-e ects logistic regression models. Absolute di erences between the sensitivity or specificity and the P values were reported from the model. In instances where only one study was available per test or when tests were being directly compared following summing of counts of the 2x2 tables, we performed test comparison using the two-sample test of proportions.

We performed three sensitivity analyses. First, estimation of sensitivity for molecular tests was made with and without studies that only evaluated samples with RT-PCR-confirmed SARS-CoV-2 (and thus did not estimate specificity). Secondly, comparisons were made between analyses using the primary reference standard and analyses using results adjusted a er sample retesting with a second RT-PCR test, either for discrepant cells (discrepant analysis) or for all samples. Thirdly, we restricted our analysis comparing ID NOW (Abbott Laboratories) and Xpert Xpress (Cepheid Inc) to studies that compared the tests in the same samples.

We made no formal assessment of reporting bias.

We summarised key findings in a 'Summary of findings' table indicating the strength of evidence for each test and findings, and highlighted important gaps in the evidence.

We are aware of additional studies published since the search date of 25 May 2020 and plan to update this review imminently. We have already completed searches for the update up until 22 June 2020, and screening of those is ongoing.

We screened 19,092 unique records (published or preprints) for inclusion in the complete suite of reviews to assist in the diagnosis of COVID-19 (Deeks 2020; McInnes 2020). Of 808 records selected for further assessment for inclusion in any of the four molecular, antigen or antibody test reviews, we assessed 90 full-text reports for inclusion in this review. See Figure 1 

We contacted the authors of three included studies for further information (Diao 2020; Porte 2020; Weitzel 2020 [A] ), and received replies and the requested information in regard to all three.

The 22 included study reports relate to 18 separate studies, four studies having both preprints and subsequent journal publications (Broder 2020; Mertens 2020; Porte 2020; Smithgall 2020 [A] ). Of the 18 studies, five are available only as preprints. (Please note when naming studies, we use the letters [A] , [B] , [C] etc. in square brackets to indicate data on di erent tests evaluated in the same study).

The 18 studies include a total of 3198 unique samples, with 1775 samples with RT-PCR-confirmed SARS-CoV-2 (some samples were analysed by more than one index test). Five studies evaluated antigen tests (Diao 2020; Lambert-Niclot 2020; Mertens 2020; Porte 2020; Weitzel 2020 [A] ) and 13 studies evaluated molecular tests (Assennato 2020; Broder 2020; Harrington 2020; Hogan 2020; Lieberman 2020; Loe elholz 2020; Mitchell 2020; Moore 2020; Moran 2020; Rhoads 2020; Smithgall 2020 [A] ; Wolters 2020; Zhen 2020 [A] ). Summary study characteristics are presented in Table  1 with further details of study design and index test details in Appendix 7 and Appendix 8. Full details are provided in the Characteristics of included studies table.

The median sample size of the included studies is 112 (interquartile range (IQR) 96 to 198) and median number of SARS-CoV-2 confirmed samples included is 85 (IQR 50 to 119). The majority of studies (10/18) were conducted in the USA, four in Europe, two in South America, one in China and one study included samples from more than one country.

Studies predominantly selected samples from those submitted to laboratories for routine RT-PCR testing with limited detail of the participants providing the samples. Three studies included samples from participants in emergency department or urgent care settings, three included samples from participants presenting in mixed settings (inpatient, outpatient or emergency department), and 12 did not report any details of setting in which study participants presented.

Four studies included samples from symptomatic patients, only one of which provided any information on the type of symptoms experienced and time from symptom onset (median 2 days; IQR 1 to 4; range 0 to 12; Porte 2020). Three additional studies provided basic demographic data such as age or gender, and the remaining 14 provided no information on participant characteristics.

All five studies evaluating antigen tests reported results for SARS-CoV-2-confirmed samples with high and low viral load as defined by the cycle threshold (Ct) value from the reference standard. In one study (Diao 2020), the proportion with high viral load was 27% (cut-o ≤ 30 Ct), and in the other four (using a cut-o of ≤ 25 Ct) it ranged from 48% to 74% (Appendix 7). Four studies reporting five molecular assay evaluations, reported proportions with high viral load ranging from 33% (Mitchell 2020), to 60% (Smithgall 2020 [A] ). All four studies defined high viral load as Ct of 30 or less. Ct values were missing for some samples in Porte 2020.

We found it di icult to fully ascertain whether samples were included in studies with or without knowledge of whether patients did or did not have COVID-19 infection. All studies defined the presence or absence of COVID-19 infection based on RT-PCR, with a single (n = 17) or two (n = 1) negative RT-PCR results used to confirm the absence of infection. One study used paired nasopharyngeal swabs for RT-PCR and nasal swabs for the index test (Harrington 2020); all other studies used the same respiratory sample for the RT-PCR and for the index test.

Nine studies appeared to include series of samples submitted for laboratory testing regardless of the RT-PCR result, but only Harrington 2020 reported including consecutive samples, and only Mertens 2020 randomly selected samples. The number of samples in these single-group studies ranged from 26 to 524 with between 13 and 208 samples with confirmed SARS-CoV-2 (median prevalence 50%; IQR 41% to 68%).

Seven studies described deliberate separate sampling of RT-PCRpositive and RT-PCR-negative samples, for example, to 'enrich' for positive samples, to reach a stated ratio of positive to negative samples, or to represent a range of Ct values on RT-PCR. We designated these studies as two-group studies. Sample sizes of these studies ranged from 88 to 481 with between 57 and 220 samples with confirmed SARS-CoV-2 (median prevalence 60%; IQR 46% to 66%).

Two studies included only samples with confirmed SARS-CoV-2, thus only allowing estimation of sensitivity; 35 samples in Broder 2020, and 96 in Rhoads 2020.

Fi een studies evaluated only one test, three compared two or more tests using the same samples (two with two tests each, and one with four tests). In total the 18 studies reported on a total of 23 test evaluations. Appendix 9 provides details extracted from the manufacturer's instructions for use documents for all included tests.

Five studies reported eight evaluations of antigen tests (4 CGIA and 4 FIA), seven of which evaluated one of five commercially produced tests (produced by Beijing Savant, Shenzhen Bioeasy, Coris BioConcept, Liming Bio-Products and RapiGEN Inc.) and one classified as using an in-house CGIA method (full identification details for all tests is provided in Appendix 8) . Contact with the study author indicates that this study reports the development of the Shenzhen Bioeasy assay (Diao 2020), but it is not clear whether the commercially available assay is identical to the one reported in the study or whether it has undergone further refinement. Only two studies provided product codes for the tests evaluated (Porte 2020; Weitzel 2020 [A] ; Appendix 8 Cochrane Database of Systematic Reviews and one study (Mertens 2020), used mixed swab samples including nasopharyngeal swabs, nasopharyngeal aspirate and bronchoalveolar lavage. All studies used samples either in viral transport medium (n = 4) or in saline solution (n = 1; Diao 2020). The Coris BioConcept assay, evaluated in two studies (Lambert-Niclot 2020; Mertens 2020), is the only one to document instructions for use for swabs in viral transport medium (VTM); the use of VTM is not mentioned in the instructions for use documents for any of the other assays (Appendix 9). Samples were tested "soon" a er collection in Lambert-Niclot 2020, a er a defined period of refrigerated storage in Porte 2020 or frozen storage in Weitzel 2020 [A] ; two studies did not report sample storage and timing of testing. In the 13 studies, seven used only nasopharyngeal (n = 6) or nasal (n = 1) swab samples, one used both nasopharyngeal and oropharyngeal swab samples from all patients, and the remaining five evaluations used mixed swab samples including nasopharyngeal or nasal swabs (n = 3), nasopharyngeal or oropharyngeal swabs (n = 1), or multiple sample types including tracheal aspirate (n = 1). One study reported direct swab testing (Harrington 2020), 10 used either swabs in viral transport medium (n = 5), viral transport medium or saline (n = 4), or viral transport medium or gelatin-lactalbumin-yeast (GLY) medium (n = 1), and two did not report whether any transport medium was used. Five of 13 studies reported testing immediately (n = 1), or within 48 (n = 1) or 72 hours (n = 3) of sample collection. Four studies reported testing a er a period of frozen storage, and four did not describe sample storage or timing of testing at all. Two of the four manufacturers document instructions for use for samples in transport medium (for the Xpert Xpress and SAMBA II assays) and two explicitly recommend against the use of viral transport medium (ID NOW and Accula), although at the time of the test evaluations, some viral transport media were documented as acceptable for ID NOW.

Although immediate sample testing is preferred, all manufacturers document acceptable period of refrigerated storage of between 24 hours (ID NOW) and seven days (Xpert Xpress). See Appendix 9.

Across the 23 test evaluations of antigen or molecular tests, only one reported testing outside of a centralised laboratory setting, where direct swab testing (using ID NOW (Abbott Laboratories)) was carried out by on-site medical personnel or laboratory personnel at local laboratories (Harrington 2020).

Our own assessment of test complexity across test types classified SAMBA II as high complexity (more than two sample preparation steps and more than three test steps), Shenzhen Bioeasy FIA, ID NOW and Accula as moderate complexity and the other antigen tests and Xpert Xpress as low complexity (one sample preparation step and up to two test steps).

We report the overall methodological quality assessed using the QUADAS-2 tool for all included studies (n = 18) in Figure 2 (Whiting 2011). See Appendix 10 for a plot of study-level ratings by quality.

We considered the risk of bias in the individual studies and whether the results were likely to be applicable to standard use of the tests. We did not judge any study at low risk of bias and we had concerns about the applicability of results in all studies. We considered risk of bias to be high in nine (50%) studies because of how they selected samples and in 13 (72%) because they considered that one negative RT-PCR was su icient to confirm the absence of COVID-19 infection. Lack of details in reporting meant we could not clearly assess whether there was a risk of bias through performance of the index test in 11 (61%) studies, or from the way in which the study was undertaken and analysed in 10 (56%). We judged that there were high concerns about the applicability of the evidence related to participants in 13 (72%) studies, to the index test in 13 (72%) studies and to the reference standard in 17 (94%) studies. We did not observe di erences in methodological quality between antigen and molecular test evaluations. Explanations of how we reached Library Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews these judgements are given below and in the Characteristics of included studies table.

We judged only two studies to be at low risk of bias, and in seven (39%) the risk was unclear because of poor reporting. The remaining 50% (9/18) we judged to be at high risk of bias because of deliberate sampling of participants based on the reference standard result; two of which also only included samples with confirmed COVID-19 infection. We were not able to judge the appropriateness of study exclusions (16/18) or inclusions (11/18) where selection was based on the availability of laboratory samples with no participant eligibility criteria specified. Numbers per group are not mutually exclusive.

We had high concerns about the applicability of the selected participants in 13/18 studies (72%), meaning that the participants who were recruited were unlikely to be similar to those in whom the test would be used in clinical practice. This was largely because of the use of deliberate sampling; and sample inclusion based on the availability of residual and sometimes frozen samples, created unrepresentative participant samples. We judged only one study recruiting participants presenting to urgent care or emergency departments as likely to have selected an appropriate patient group. Figure 2 demonstrates similar patterns in risk of bias and applicability of the index test for studies of both antigen and rapid molecular tests. We observed low risk of bias in four studies that clearly described interpretation of the index test blinded to results of the reference standard, and used prespecified test thresholds. There was high risk of bias in three studies because the manufacturer's prespecified threshold for the Xpert Xpress test (re-testing of samples with presumptive positive results) was not followed. The risk of bias was unclear in 11 studies because we could not judge whether interpretation of the index test was undertaken with knowledge of whether individuals did or did not have COVID-19 infection.

Thirteen studies did not carry out testing as it would occur in practice: four studies used trained, centralised laboratory sta and not local laboratory or healthcare personnel; one test could not be purchased (Diao 2020); and 11 because the test was not conducted within the manufacturer instructions for use (these categories are not mutually exclusive). Four studies tested samples in a viral transport medium that was not covered by the manufacturer instructions for use, five used frozen samples, one reported heat inactivation of samples prior to direct testing and two reported a testing timeframe beyond that recommended.

The remaining five studies provided inadequate information to make a judgement; three of them did conduct the test within the manufacturer instructions for use but none of them clearly described the setting for testing or personnel conducting the test.

Only one study used an appropriate reference standard to define the presence or absence of COVID-19 infection (two negative PCR results required to confirm the absence of COVID-19) and implemented it in ways that prevented bias (Diao 2020). One additional study reported two RT-PCR results for all study participants (Moore 2020), and two did not include non-COVID-19 cases. We considered that the remaining 14 did not use an adequate reference standard, putting them at high risk of bias ( Figure 2 ). Eight studies reported blinded RT-PCR interpretation and 10 (56%) provided insu icient information about blinding of the reference standard to the index test to judge risk of bias.

RT-PCR is unlikely to falsely classify participants as having COVID-19 (low risk of false positive), but may miss true cases leading to false positives on the index test when a single RT-PCR alone is used as a reference standard. Four studies (22%) used a second RT-PCR test for samples with discrepant results (FP and FN) to address this. However, selective re-testing could miss additional cases of COVID-19 infection, and is likely to lead to distorted results. One study (Moore 2020), used a second RT-PCR test in all samples and furthermore carried out a record review for all cases with discrepant results in order to verify whether participants were truly considered to have had COVID-19 infection.

We judged 17 of the 18 studies to raise concerns for applicability (94%) because of defining the presence of COVID-19 infection based on a single RT-PCR-positive result. These studies will have excluded individuals who are RT-PCR-negative but have exposure and clinical features that meet the case definitions for COVID-19.

Only three studies were at low risk of bias for participant flow and timing, one (Porte 2020), used a Standards of Reporting Diagnostic Accuracy Studies (STARD)-style participant flow diagram and checklist (Bossuyt 2015), to fully report outcomes for all samples. Five studies were at high risk of bias because of exclusion of samples following invalid index test results (they did not carry out any retesting).

Unclear risk of bias was present in 10 (56%) studies because of lack of clarity around participant inclusion and exclusion from analyses. Six studies were unclear regarding whether the analysis was participant-based or sample-based (where there is a possibility of multiple samples per participant overstating the precision of estimates).

In six studies all authors declared no conflicts of interest, although one study that evaluated an 'in-house' test included a co-author a iliated to a test manufacturing company. Eight studies did not provide a conflict of interest statement (one of these included co-authors a iliated to the test manufacturer) and in the four remaining studies at least one author declared conflicts of interest in relation to the test.

Eleven studies provided no funding statement, five reported no funding sources to declare, and two reported one or more public funding sources. Two studies reported receipt of test kits or reagents 'in kind' from test manufacturers.

Of the 18 included studies, three reported evaluations of more than one test using the same samples ( We undertook analyses separately for antigen tests and for molecular-based tests. We present results for all analyses in Table  2 . Forest plots of study data for the primary analyses are in Figure  3 and Figure 4 . Full identification details for all assays are provided in Appendix 8 and Appendix 9); for brevity, the antigen assays are referred to by the manufacturer name. Subgroup analyses according to viral load are in Figure 5 and Figure 6 , and rapid molecular test results before and a er discrepant analysis are in Figure 7 . Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews

Average sensitivity across the eight evaluations of antigen tests was 56.2% (95% CI 29.5 to 79.8%), and average specificity 99.5% (95% CI 98.1% to 99.9%; 943 samples, including 596 samples with confirmed SARS-CoV-2; Table 2 ). However, Figure  3 shows considerable heterogeneity in sensitivity, with results across studies ranging from 0% to 94%. The average value should therefore be interpreted with caution as there may be real di erences in sensitivity between the test brands. The two assays with lowest sensitivity (Liming Bio-Products and Beijing Savant assays) do not now appear to be commercially available. Pooled results for the two tests with two studies each suggested higher sensitivity for the Shenzhen Bioeasy FIA (89.5%, 95% CI 83.7% to 93.8%) than the Coris BioConcept CGIA (54.4%, 95% CI 47.7% to 61.0%), but these tests were not evaluated in the same studies and other factors may explain the observed di erences. Similar, unknown factors may explain di erences between the Shenzhen Bioeasy and Coris BioConcept assays and the other tests for which only single studies were available. Specificities were consistent and high, with point estimates of 99% or 100% in seven evaluations, and one study estimating specificity as 90% but with a 95% confidence interval that included 100%.

Average sensitivity and specificity for the 13 rapid molecular test evaluations that included samples with and without SARS- 

Adequate data for di erent sample types were available for studies using nasopharyngeal samples only. We observed similar average sensitivity (59.4%, 95% CI 50.7% to 67.5%) and specificity (99.6%, 95% CI 97.4% to 99.9%) for three evaluations of antigen tests (705 samples, 434 with confirmed SARS-CoV-2). For six evaluations of molecular tests, average sensitivity appeared lower compared to the overall pooled estimate (87.1%, 95% CI 71.6% to 94.7%) with little change in specificity ( Table 2) .

We extracted sensitivity data according to viral load from seven evaluations of antigen tests (three with the assistance of the study authors) and five evaluations of molecular tests. Ct threshold for high viral load was 25 or less for four of the five antigen studies and 30 or less for the remaining antigen evaluation and for all of the molecular assay evaluations. We observed a large di erence in sensitivity in the high viral load group (400 with confirmed SARS-CoV-2) for antigen tests (di erence of 60. 6 Cochrane Database of Systematic Reviews confirmed SARS-CoV-2) that was beyond that expected by chance (P < 0.001) (Table 2; Figure 5 ).

For molecular tests, all sensitivity estimates for the high viral load subgroups were 100% (based on 151 samples with confirmed SARS-CoV-2) compared to between 34% and 100% for low viral load subgroups (summary sensitivity 93.3%, 95% CI 46.7% to 99.6%; 142 samples with confirmed SARS-CoV-2; Table 2 ; Figure  6 ). The evaluations with the lowest sensitivities both evaluated ID NOW, with reported sensitivity estimates of 34% (35 samples with confirmed SARS-CoV-2 in Smithgall 2020 [A] ), and 58% (based on 31 samples with confirmed SARS-CoV-2 in Mitchell 2020). Sensitivity in the three evaluations of Xpert Xpress ranged from 97% (35 samples with confirmed SARS-CoV-2 in Smithgall 2020 [B] ) to 100% (in Lieberman 2020 and Wolters 2020, with 7 and 34 samples with confirmed SARS-CoV-2 respectively).

Four evaluations of molecular tests (in 1566 samples) reported results before and a er discrepant analysis where selected samples were re-tested with either the same (Harrington 2020; Moran 2020), or an alternative RT-PCR assay (Assennato 2020; Loe elholz 2020), three of which also reported re-testing of samples with the index test (Assennato 2020; Harrington 2020; Moran 2020; Table 3 ; Figure  7 ).

Discrepant analysis always works to reduce the number of samples deemed to be false negative or false positive errors. Discrepant analysis reduced the false negative proportion (1-sensitivity) from 1.8% to 0.5% and the false positive rate (1-specificity) from 2.2% to 0.4%. Three of the four studies reporting initially 'false positive' results reported zero false positives a er sample re-testing and one reported a drop in false positives from 11 to 3 (Loe elholz 2020; Table 3 ). One of the two studies reporting re-testing of initially 'false negative' results reported reclassification as true negative on re-testing, and in the other the false negative remained as a false negative. Given the bias inherent in choosing the reference test dependent on the observed results, we caution against these findings.

An additional study tested all samples with two di erent RT-PCR assays, and hence used a more accurate reference standard in all samples, not just samples with discrepant results (Moore 2020), in which six initial true negatives were reclassified as false negatives a er the second RT-PCR. Had discrepant analysis been undertaken these misclassifications would have been missed, further underlining the methodological flaws inherent to discrepant analysis.

We planned to evaluate the e ect of other sources of heterogeneity, including study design, reference standard, length and severity of symptoms, and setting. However, additional formal investigations using meta-regression were not possible because of limited data, lack of reporting or lack of variability across the studies in these features (Appendix 11). Only one study reported the median time to testing a er symptom onset, none reported symptom severity, and three reported the setting in which tests were conducted. All studies used RT-PCR alone as the reference standard for diagnosing COVID-19 infection.

We anticipate revisiting the e ect of study design and including a more detailed investigation by sample type in future iterations of this review.

This is the first version of a Cochrane living review summarising the accuracy of point-of-care antigen and molecular tests for detecting current SARS-CoV-2 infection. This version of the review is based on published studies, or studies available as preprints, up until 25 May 2020. We are continually identifying new published studies, and plan regular updates of this review.

We included data from 18 studies including 3198 samples (including 1775 samples with confirmed SARS-CoV-2). Five studies, reporting eight test evaluations, considered antigen tests and 13 studies, reporting 15 test evaluations, considered rapid molecular tests. Key findings are presented in the Summary of findings 1.

We summarise five key findings from this review.

1. A significant proportion of antigen and molecular assays that are suitable for use at the point of care do not have any published or preprint reports of accuracy. This review has evaluated data from five commercial antigen tests, two of which we could not identify as available for purchase, and four molecular assays.

These represent a small proportion of assays currently available. We have identified 24 additional studies of rapid antigen or molecular tests published or available as preprints up until 22 June 2020, which we will appraise for inclusion in the review update, but there still remain no published data for the majority of tests on the current FIND list. 2. The design and execution of studies limits the strength of conclusions that we are currently able to draw, either for antigen or for molecular tests. It is unclear whether the limitations in the primary studies will lead to over-or under-estimates of test accuracy, thus all results we report should be interpreted with a high degree of caution. Half of studies used deliberate sampling based on the presence or absence of confirmed COVID-19 infection, and the majority selected samples from those submitted to laboratories for routine RT-PCR testing with little to no detail of the participants who provided the samples in relation to either symptom status or time from symptom onset. It is impossible to determine the e ect of inclusion decisions based on the availability of residual or remnant samples. It was not always clear how many samples were included from each participant, and the analysis had to be undertaken on a per-sample basis, which will have overestimated the precision of the estimates. RT-PCR was the only reference standard for diagnosing the presence of SARS-COV-2 infection so that we are unable to comment on the accuracy of rapid tests for diagnosing infection in those who are RT-PCR negative but meet case definition criteria for the presence of infection. The use of a second RT-PCR assay to determine the disease status of samples with discrepant results following rapid molecular testing is likely to introduce further bias. 3. Three-quarters of studies conducted tests outside of manufacturers' instructions for use, particularly in regard to sample storage and use of transport media, and with tests conducted in centralised laboratories rather than at the point of care, so that test accuracy in a clinical setting remains Cochrane Database of Systematic Reviews unknown. We considered five tests, including one molecular assay, to have low complexity in terms of minimal sample preparation and test steps, and the other four to have moderate (n = 3) or high (n = 1) complexity, which could also a ect how well the observed accuracy translates into practice. We did not include interpretation steps in our assessment of test complexity; however the use of reader devices, for example for FIAs, could be considered to further add to complexity. 4. On average, the sensitivity of antigen tests was relatively poor (56.2%, 95% CI 29.5 to 79.8%), but with consistently high specificities (average 99.5%, 95% CI 98.1 to 99.9%). However, there is considerable heterogeneity in sensitivities between studies, and with limited data for individual tests. We observed large di erences in sensitivity according to viral load and suspect that di erences in the distribution of samples with high and low viral load between studies may have a ected overall accuracy estimates. Combined with methodological limitations and other unknown factors, it is not possible to state with any certainty whether any test is superior to the others. There is a suggestion of higher sensitivity in two studies of the Shenzhen Bioeasy fluorescent immunoassay (sensitivity 89.5%, 95% CI 83.8%, 93.3%), that was maintained in subgroup analysis by viral load (one of the two obtained over 90% of samples during the first week of symptoms). An additional study reporting the development of this assay reported lower sensitivity overall (68%, 95% CI 61, 74%), however it included a much lower proportion of samples with high viral load (27% compared to 68 to 74% in the other two studies). Subgroup analysis suggested the test performed similarly to the other two studies when restricted to high and low viral load subgroups. All three studies included high percentages of samples with confirmed SARS-CoV-2, and more data is needed to determine whether test performance for this assay can be repeated in clinical practice. 5. On average, the sensitivity for the rapid molecular tests was 95.2% (95%CI 86.7%, 98.3%) with specificity 98.9% (95% CI 97.3, 99.5%). Although the average estimates are based on twice as much data as for the antigen tests, the evaluations are subject to the same methodological limitations, and we do not know how the assays would perform in any specific clinical setting when used in people suspected of having COVID-19 infection or of having been exposed to a confirmed case.

Most of the evaluations of molecular tests were of ID NOW or Xpert Xpress. Summary sensitivity for Xpert Xpress (99.4%, 95% CI 98.0 to 99.8%) was 22.6 percentage points higher than that of ID NOW, a magnitude of di erence that was more or less maintained in the two direct comparisons of the two assays. Concerns over risk of bias would suggest that this high rate of sensitivity might be an over-estimate. However as both sets of studies have similar methodological limitations, it is probably reasonable to presume that some di erence in sensitivity between tests would be maintained if these sources of bias were removed. The di erence in specificity between the tests is small (ID NOW being 2.8% more specific compared to Xpert Xpress), but potentially important especially if used in a low-prevalence setting. However, this would not be an issue should test positives be confirmed by a laboratorybased RT-PCR assay. Concerns about the applicability of study participants and index tests brings into question whether similar di erences in test performance would be observed in practice.

As stated above, we did not undertake a formal comparison between antigen and molecular assays because of the lack of direct head-to-head comparisons of the two test types. However, the possible e ect of the observed di erences in accuracy can be illustrated by applying the summary estimates of test accuracy to a hypothetical cohort of 1000 people suspected of COVID-19 infection (Summary of findings 1). If 100 people had confirmed SARS-COV-2 infection (prevalence of 10%), the average sensitivity and specificities of antigen tests mean that 5 of 61 people with a positive test result would be false positives (positive predictive value (PPV) 92%) while 44 of 940 people with negative test results would be falsely negative (negative predictive value (NPV) 95%). As there is high heterogeneity in the estimates of sensitivity, the values observed in practice could vary considerably from these figures. For molecular assays at the same prevalence, 10 of 105 positive test results would be false positive (PPV 90%), and 5 of 895 with negative results would be falsely negative (NPV 99%).

Small decreases (to 5%) or increases (to 20%) in prevalence make little di erence to the absolute number of false positive results, but have a large relative e ect when considered in relation to the number of positive test results (PPV ranging 85% to 97% for antigen tests and 83% to 95% for molecular assays). The NPV (percentage of negative test results that are truly negative) for the molecular assays is not a ected by these prevalence changes in the same way because of the relatively high sensitivity and relatively low-prevalence scenarios considered. Wider variation is observed for antigen tests (98% to 90%). This shows how even in a low-prevalence setting, tests with poor sensitivity can have a considerable impact on the level of confidence that can be had in a negative test result. However, we emphasise that these numbers are not based on any evidence comparing antigen and molecular tests in the same samples.

We saw a similar pattern of results when applying summary results for individual tests with wide variations in sensitivity and only small di erences in specificities (Summary of findings 1).

Our review used a broad search screening all articles concerning COVID-19. We undertook all screening and eligibility assessments, QUADAS-2 assessments (Whiting 2011), and data extraction of study findings independently and in duplicate. Whilst we have reasonable confidence in the completeness and accuracy of the findings up until the search date, should errors be noted please inform us at coviddta@contacts.bham.ac.uk so that we can check and correct in our next update.

We identified one other systematic review of point-of-care tests for detection of SARS-CoV-2 that is currently available only as a preprint (Subsoontorn 2020). The review did not consider antigen tests or RT-PCR-based tests (such as Xpert Xpress), instead focusing on molecular tests that do not require the use of a thermal cycler. We undertook a careful assessment of test complexity to ensure that included tests were suitable for use at the point of care. This assessment included explicit consideration of sample preparation and biosafety requirements as well as time to test result. The application of these index test criteria led to the exclusion of the majority of the 31 RT-LAMP or CRISPr assay evaluations that were included in Subsoontorn 2020. Evaluations of alternative laboratory-based molecular technologies are under consideration for inclusion in another review in our series of Cochrane COVID-19 DTA reviews. An additional seven studies included in Subsoontorn Cochrane Database of Systematic Reviews 2020 became available a er our search cut-o and are already under consideration for inclusion in the review update.

Weaknesses of the review primarily reflect the weaknesses in the primary studies and their reporting. Many studies omitted descriptions of participants, and key aspects of study design and execution. In order to include data for all tests in pooled analyses we have had to include some samples multiple times. We have been explicit about these issues where they arose. It is possible that eligible studies have been missed by our search strategy however we believe the risk to be very low considering our broad approach to identification of literature.

Around a quarter (5/18) of the studies we have included are currently only available as preprints, and as yet, have not undergone peer review. As published versions of these studies are identified in the future, we will double-check study descriptions, methods and findings, and update the review as required.

We have concerns about the applicability of the evidence that we have identified for point-of-care tests.

Due to lack of reporting, we do not know whether tests perform in the same way or di erently according to whether those being tested have symptoms of COVID-19, and if so how long they have experienced those symptoms for, or are asymptomatic. Studies appeared to include remnant or residual samples for testing and many selectively included high percentages of samples with RT-PCR-confirmed SARS-CoV-2. In reality, point-of-care tests will be considered for use in much lower prevalence settings.

Methodological work on diagnostic test evaluations has shown that independently of prevalence, tests do not necessarily exhibit the same sensitivity and specificity in di erent prevalence settings (Usher-Smith 2016). This can be because of di erences in the case-mix or 'spectrum' of disease (e.g. viral load). However, the mechanisms in action can be complex and di icult to clearly identify (Leeflang 2013).

We also had concerns about the way in which many of the tests evaluated were performed outside of manufacturer instructions for use, and not in fact at the point of care.

Great caution should be taken in applying these results outside of the individual study contexts.

In the Role of index test(s) section, we suggested two main roles for point-of-care testing.

1. As a replacement for laboratory-based RT-PCR, if su iciently accurate. Evidence included to date suggests that some rapid molecular tests might have accuracy levels approximating those of laboratory-based RT-PCR. However, many of the data come from two-group studies with deliberate over-sampling of cases and concerns over the applicability of the evidence. We cannot be certain as to whether any test performs su iciently well for this role. 2. As a triage to RT-PCR, allowing earlier detection and rapid management (self-isolation, quarantine or therapeutic intervention) of those testing positive; those with negative results waiting for the laboratory-based RT-PCR result. On current evidence of test performance (using average observed sensitivities and specificities), rapid tests could only perform this type of triage role in higher-prevalence settings (i.e. 20% or higher) because of the (relative) risk of false positive results in lower-prevalence settings. Although average test specificities are high for both antigen and for molecular tests, unnecessary quarantine measures for 1 in 6 (83% PPV), or even 1 in 10 (90% PPV), people with a positive test result would seem a relatively high price to pay for a rapid result. The 99% to 100% specificities observed for individual tests would need to be replicated in well designed field studies, and following manufacturers' instructions for use, before any test could be recommended for use as a triage test.

Alternatively, serial testing (over a number of days), or combinations of di erent rapid tests (e.g. an antigen test followed by a rapid molecular test) on the same sample may provide a useful testing strategy; however, additional evidence of the performance of any such diagnostic strategy would be needed. In the absence of further evidence, and in low prevalence settings, both positive and negative results from any of the rapid point-of-care tests included in this review would need to be followed up with a laboratory-based RT-PCR.

Ultimately, decisions around rapid testing will be driven not only by diagnostic accuracy but by acceptable levels of test complexity, time to result, and acceptability to those being tested, all of which might vary according to the setting in which the tests are to be used. In settings where RT-PCR is not available, rapid tests may have a role if accpetable performance targets for diagnostic test accuracy, such as those laid out in WHO's priority target product profiles for COVID-19 diagnostics, can be met (WHO 2020c).

A considerable volume of research has already emerged for pointof-care tests for COVID-19 infection. However further prospective and comparative evaluations of individual tests, either alone or in combination, and in clinically relevant settings are urgently needed. These settings include those where people with signs and symptoms present for testing as well as those involving testing asymptomatic people who may have come into contact with confirmed cases. Reliable and ideally rapid diagnostic tests are the keystone to good track and trace programmes, as a means of implementing necessary self-isolation or quarantine and reducing community transmission. Studies should recruit consecutive series of eligible participants and should clearly describe symptomatic status, and should document time from symptom onset or time since exposure. Point-of-care tests must be conducted in accordance with manufacturer instructions for use, and across the spectrum of point-of-care settings and test operators.

We observed a number of studies of molecular assays employing discrepant analysis to confirm the disease status of samples with false positive results in particular. There is a considerable risk of this type of selective re-testing leading to distorted results. If there is su icient concern about the reliability of a single RT-PCR test then all samples should be tested with two RT-PCR assays. Finally, any future research study needs to be clear about eligibility and exclusion decisions throughout the whole diagnostic pathway, 

Members of the Cochrane COVID-19 Diagnostic Test Accuracy Review Group include:

• the project team (Deeks JJ, Dinnes J, Takwoingi Y, Davenport 

World Health Organization. Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance. Available from www.who.int/publications/i/item/ laboratory-testing-for-2019-novel-coronavirus-in-suspectedhuman-cases-20200117 2020.

Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance. Available from www.who.int/publications/i/item/global-surveillance-forcovid-19-caused-by-human-infection-with-covid-19-virusinterim-guidance 2020.

COVID-19 Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.0.1. Available from www.who.int/publications/m/item/covid-19-targetproduct-profiles-for-priority-diagnostics-to-support-responseto-the-covid-19-pandemic-v.0.1 2020.

Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 2020;369:m1443.

* Indicates the major publication for the study Cochrane Database of Systematic Reviews

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Reference standard does not incorporate result of index test?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard? 

Are there concerns that the included patients and setting do not match the review question?

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition? 

Unclear risk

Unclear

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests? 

Low concern DOMAIN 2: Index Test (Antigen tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it pre-specified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Harrington 2020 (Continued) 

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Yes Did all patients receive the same reference standard?

Did all participants receive a reference standard?

Were results presented per patient? Yes

Harrington 2020 (Continued) 

Are there concerns that the included patients and setting do not match the review question?

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Reference standard does not incorporate result of index test?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Hogan 2020 (Continued) 

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Yes Did all patients receive the same reference standard?

Were all patients included in the analysis? Unclear Did all participants receive a reference standard?

Were results presented per patient? Yes

Hogan 2020 (Continued) 

Are there concerns that the included patients and setting do not match the review question?

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Reference standard does not incorporate result of index test?

Are there concerns that the target condition as defined by the reference standard does not match the question? 

Are there concerns that the included patients and setting do not match the review question?

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition? Author COI: the study was designed and supervised by the sponsor, Cepheid. Data were collected by investigators at each study site, and statistical analyses were performed by a Cepheid author. Cepheid authors wrote the first dra of the manuscript. All study authors vouch for the accuracy and completeness of the data reported.

Loe elholz 2020 (Continued) 

Are there concerns that the included patients and setting do not match the review question?

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it prespecified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Loe elholz 2020 (Continued) Yes Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Yes Did all patients receive the same reference standard?

Were all patients included in the analysis?

No Did all participants receive a reference standard?

Were results presented per patient?

Could the patient flow have introduced bias?

Loe elholz 2020 (Continued) 

Patient Sampling Single-group study to estimate sensitivity and specificity for diagnosis of active disease: Author COI: the IVD medical device has been developed by the investigator Pascal Mertens, Henri Magein, and Justine Bouzet working for Coris BioConcept (potential conflict of interest declared even though they don't have any share in this company); Thierry Leclipteux was involved in the development of this test and is the CEO of Coris Bioconcept (potential conflict of interest declared). All scientific investigators that are external to Coris BioConcept declare having no conflict of interest.

Was a consecutive or random sample of patients enrolled?

Yes Was a case-control design avoided?

Did the study avoid inappropriate exclusions? 

Did the study avoid inappropriate inclusions?

Are there concerns that the included patients and setting do not match the review question?

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Reference standard does not incorporate result of index test?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard? 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (Antigen tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Reference standard does not incorporate result of index test?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Yes Did all patients receive the same reference standard?

Were all patients included in the analysis? Unclear Did all participants receive a reference standard? Yes

Were results presented per patient? Unclear

Unclear risk Record review used to verify status of 8 samples positive on RealTime assay and negative (6) or inconclusive (2) Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it prespecified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Reference standard does not incorporate result of index test?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern

Was there an appropriate interval between index test and reference standard?

Moore 2020 (Continued) Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? No

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition? 

Are there concerns that the included patients and setting do not match the review question?

Were the index test results interpreted without knowledge of the results of the reference standard?

Yes If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Reference standard does not incorporate result of index test?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Yes Did all patients receive the same reference standard?

Were all patients included in the analysis? Yes Did all participants receive a reference standard?

Were results presented per patient? Yes

Could the patient flow have introduced bias?

Porte 2020 (Continued) 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (Antigen tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it pre-specified?

Could the conduct or interpretation of the index test have introduced bias?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Reference standard does not incorporate result of index test?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by

Wolters 2020 (Continued) Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection ( 

Wolters 2020 (Continued) 

Patient Sampling 2-group study to estimate sensitivity and specificity: -samples from symptomatic patients of all ages and gender Recruitment: not stated; specimens selected to represent the true positivity rate at authors' institution (50% to 60%), and to span low and high viral loads Prospective or retrospective: mixed; included frozen samples (n = 88) and prospectively tested (n = 20) 

Were the reference standard results interpreted without knowledge of the results of the index tests?

Reference standard does not incorporate result of index test?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Yes Did all patients receive the same reference standard?

Were all patients included in the analysis?

No Did all participants receive a reference standard?

Were results presented per patient? Unclear

High risk

Patient Sampling See Zhen 2020 [A] for full study details and QUADAS entries Patient characteristics and setting See Zhen 2020 [A] for full study details and QUADAS entries Index tests Zhen 2020 [B] is the entry for test [B] from the list below, see Zhen 2020 [A] for full study details and QUADAS entries SARS-CoV-2 negative on RT-PCR retest *authors note that viral loads were at the limit of detection for Xpert Xpress and that multiple freeze-thaw steps of samples could have had a significant impact on detection. 

In areas with no known COVID-19 virus circulation confirmation requires:

• NAAT positive for at least two different targets on the COVID-19 virus genome, of which at least one target is preferably specific for COVID-19 virus (or SARS-like coronavirus) using a validated assay; OR • NAAT-positive result for betacoronavirus, and COVID-19 virus identified by sequencing partial/whole genome of virus (sequence target larger or different from the amplicon probed in the NAAT assay).

Discordant results should be resampled. In areas where COVID-19 virus is widely spread a simpler algorithm might be adopted (e.g. RT-PCR of a single discriminatory target)

talisation and an absence of alternative explanation virus is inconclusive OR A suspect case for whom testing could not be performed for any reason.

could support diagnosis once validated serology tests are available.

Serological assays will play an important role in research and surveillance but are not currently recommended for case detection.

NAAT: nucleic acids amplification test; RT-PCR: reverse transcription polymerase chain reaction. This will be similar for all index tests, target conditions, and populations.

Yes: if a study explicitly stated that all participants within a certain time frame were included; that this was done consecutively; or that a random selection was done.

Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews

We planned to check the following websites for eligible index tests, however these did not prove to be very accessible or easy to use and, a er initial review, were not further considered:

• National Institute for Health Research (NIHR) Innovation Observatory (www.io.nihr.ac.uk/) • www.rapidmicrobiology.com/test-method/testing-for-the-wuhan-coronavirus-a-k-a-covid-19-sars-cov-2-and-2019-ncov

We planned to check the following evidence repository for additional eligible studies however, the EPPI-Centre and Norwegian Institute of Public Health resources proved to be more accessible therefore we decided to prioritise our other sources of evidence.

• Meta-evidence (meta-evidence.co.uk/the-role-of-evidence-synthesis-in-covid19/)

We intended for two authors to independently perform data extraction, however one review author extracted study characteristics, and a second author checked them. Contingency table data were extracted independently by two review authors as planned.

We planned to evaluate the e ect of additional sources of heterogeneity, including study design, reference standard, length and severity of symptoms, and setting. However, additional formal investigations using meta-regression were not possible because of limited data, lack of reporting or lack of variability across the studies in these features.

We planned to conduct a sensitivity analysis excluding studies that are solely published as preprints. We have inadequate study numbers to allow this at present but will reconsider for the next update.

Performance evaluation of the point-of-care SAMBA II SARS-CoV-2 test for detection of SARS-CoV-2. medRxiv

Reference standard: RT-PCR (sites using each kit not reported, added by review team based on number of samples per site and per RT

New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel; NYC 2. Quest SARS-CoV-2 rRT-PCR (Quest Diagnostics

Los Angeles 3. RealStar® SARS-CoV-2 RT-PCR Kit 1.0 (Altona Diagnostics

GeneFinder COVID-19 Plus RealAmp Kit

Allplex 2019-nCoV Assay

Simplexa COVID-19 Direct

Newark Definition of non-COVID cases: yes (performed prior to index test) Genetic target(s): different targets depending on RT-PCR test used

RealStar ; S, E Reference standard: RT-PCR; 2 methods used in the study 1. modified CDC RT-PCR (positive result required Ct < 40 for both targets; negative if neither target detected and positive amplification curve for control (RP) gene

Patient characteristics and setting Index tests Weitzel 2020 [B] entry is for test [B] in the list below; see Weitzel 2020 [A] for full study details and QUADAS entries Test name

COVID-19 Antigen Rapid Test Device StrongStep COVID-19 Antigen Test

Manufacturer

Anyang-si

China Antigen target: not reported in study Antibody: not reported in study Test method

Test operator: single, trained laboratory technician under BSL2 cabinet

full study details and QUADAS entries Index tests Weitzel 2020 [C] entry is for test [C] in the list below; see Weitzel 2020 [A] for full study details and QUADAS entries Test name

COVID-19 Antigen Rapid Test Device StrongStep COVID-19 Antigen Test

Manufacturer

Anyang-si

China Antigen target: not reported in study Antibody: not reported in study Test method

Test operator: single, trained laboratory technician under BSL2 cabinet

] for full study details and QUADAS entries Test name

COVID-19 Antigen Rapid Test Device StrongStep® COVID-19 Antigen Test

Huaketai New Coronavirus (SARS-CoV-2) N Protein Detection Kit (Fluorescence immunochromatography

Manufacturer

Anyang-si

China Antigen target: not reported in study Antibody: not reported in study Test method

Test operator: single, trained laboratory technician under BSL2 cabinet; visual outputs read by 2 independent observers with referral to third if needed 1. New York SARS-CoV-2 Real-time RT-PCR Diagnostic Panel

Quest SARS-CoV-2 rRT-PCR (Quest Diagnostics

GeneFinder COV-ID-19 Plus Re-alAmp Kit

Germany) (in-house)

N (N1, N2) gene

N (N1, N3) gene

Jacqueline Dinnes: none known Yemisi Takwoingi: none known

René Spijker: the Dutch Cochrane Centre (DCC) has received grants for performing commissioned systematic reviews

Lotty Hoo : none known

Ann Van den Bruel: none known

FIND is a global non-for profit product development partnership and WHO Diagnostic Collaboration Centre. It is FIND's role to accelerate access to high quality diagnostic tools for low resource settings and this is achieved by supporting both R&D and access activities for a wide range of diseases, including COVID-19. .FIND has several clinical research projects to evaluate multiple new diagnostic tests against published Target Product Profiles that have been defined through consensus processes. These studies are for diagnostic products developed by private sector companies who provide access to know-how

FIND is a global non-for profit product development partnership and WHO Diagnostic Collaboration Centre. It is FIND's role to accelerate access to high quality diagnostic tools for low resource settings and this is achieved by supporting both R&D and access activities for a wide range of diseases, including COVID-19. .FIND has several clinical research projects to evaluate multiple new diagnostic tests against published Target Product Profiles that have been defined through consensus processes. These studies are for diagnostic products developed by private sector companies who provide access to know-how

Ada Adriano: none known Sophie Beese: none known Janine Dretzke: none known

Isobel Harris: none known Malcolm Price: none known Sian Taylor-Phillips: none known

Jane Cunningham: none known for International Development

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection (Review)

Copyright © 2020 The Authors

Cochrane Database of Systematic Reviews Demographics: median age 40 years; 50, 45% male (median age 38 years, 43% male for all samples tested during period) Exposure history: none reported

Weitzel 2020 [A] entry is for test [A] in the list below Test name:

Step SARS-CoV-2 Antigen Test (RapiGEN Inc., Anyang-si, Gyeonggi-do, Republic of Korea) [B] COVID-19 Antigen Rapid Test Device StrongStep COVID-19 Antigen Test (Liming Bio-Products Co., Jiangsu, China) [C] Huaketai New Coronavirus (SARS-CoV-2) N Protein Detection Kit (Fluorescence immunochromatography) (Savant Biotechnology Co., Beijing, China), [D] Diagnostic Kit for 2019-Novel Coronavirus (2019-nCoV) Ag Test (Fluorescence Immunochromatographic Assay) (Bioeasy Biotechnology Co., Shenzhen, China).Manufacturer: [A] RapiGEN Inc., Anyang-si, Gyeonggi-do, Republic of Korea [B] Liming Bio-Products Co., Jiangsu, China [C] Savant Biotechnology Co., Beijing, China [D] Bioeasy Biotechnology Co., Shenzhen, ChinaAntigen target: not reported in study Antibody: not reported in study Test method: [A] and [B] CGIA [C] and [D] Were the index test results interpreted without knowledge of the results of the reference standard?Unclear If a threshold was used, was it pre-specified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Zhen 2020 [A] (Continued) Cochrane Database of Systematic Reviews

Baek 2020 Ineligible index test 

Presented below are all the data for all of the tests entered into the review. 

Recruitment structure Single group -sensitivity and specificity 3 (60%) 6 (46%)Single group -sensitivity only 0 (0) 2 (15%) 

The following information is taken from the university of Bern website (see: ispmbern.github.io/covid-19/living-review/ collectingdata.html).The register is updated daily and CSV file downloads are made available.

From 1 April 2020, we will retrieve the curated BioRxiv/MedRxiv dataset (connect.medrxiv.org/relate/content/181). 

This will be similar for all index tests, target conditions, and populations.Yes: if a study explicitly stated that all participants came from the same group of (suspected) patients.No: if it was clear that a different selection procedure was employed for the participants depending on their COVID-19 status or SARS-CoV-2 infection status; or if only participants with SARS-CoV-2 infection were included Unclear: if the selection procedure was not clear or not reported.

Studies may have excluded patients, or selected patients in such a way that they avoided including those who were difficult to diagnose or likely to be borderline. Although the inclusion and exclusion criteria will be different for the different index tests, inappropriate exclusions and inclusions will be similar for all index tests: for example, only elderly patients excluded, or children (as sampling may be more difficult). This needs to be addressed on a case-by-case basis.Yes: if a high proportion of eligible patients was included without clear selection.No: if a high proportion of eligible patients was excluded without providing a reason; if, in a retrospective study, participants without index test or reference standard results were excluded.Unclear: if the exclusion criteria were not reported.

Some laboratory studies may have intentionally included groups of patients in whom the accuracy was likely to differ, such as those with particularly low or high viral loads, or who had other diseases, such that the sample over-represented these groups. This needs to be addressed on a caseby-case basis.Yes: if samples included were likely to be representative of the spectrum of disease.No: if the study oversampled patients with particular characteristics likely to affect estimates of accuracy.Unclear: if the exclusion criteria were not reported.

High: if one or more signalling questions were answered with no, as any deviation from the selection process may lead to bias.Low: if all signalling questions were answered with yes.

Is there concern that the included participants do not match the review question?High: for two-group studies that included healthy or other disease controls, whether pre-pandemic or contemporaneous; studies that only included people with COVID-19 (whether RT-PCR-confirmed only, participants meeting official guideline criteria);Low: for single-group studies recruiting participants with signs and symptoms of COVID-19; or for two-group studies where control groups suspected of COVID-19 were separately recruited.Unclear: if a description about the participants was lacking.

Yes: if blinding was explicitly stated or index test was recorded before the results from the reference standard were available.No: if it was explicitly stated that the index test results were interpreted with knowledge of the results of the reference standard.Unclear: if blinding was unclearly reported. Cochrane Database of Systematic Reviews

Yes: if the test was dichotomous by nature, or if the threshold was stated in the methods section, or if study authors stated that the threshold as recommended by the manufacturer was used.No: if a receiver operating characteristic curve was drawn or multiple threshold reported in the results section; and the final result was based on one of these thresholds.Unclear: if threshold selection was not clearly reported.

High: if one or more signalling questions were answered with no, as even in a laboratory situation knowledge of the reference standard may lead to bias.Low: if all signalling questions were answered with yes.

Is there concern that the index test, its conduct, or interpretation differ from the review question?For all test types, if index test is 'in-house' or not commercially available, then state 'High'. If any test procedures used in the study diverged from IFU ((use of VTM, or testing outwith stated time limit), also state High If testing carried out in centralised laboratory and not near patient then state High.Evaluations that withheld the name of the test, or that used mixed sample types or did not report the evaluation setting, state Unclear If samples used and any sample processing steps are in accordance with test IFU, or if study describes conducting the test according to the manufacturer's protocol, state Low

Is the reference standard likely to correctly classify the target condition?We will define acceptable reference standards using a consensus process once the list of reference standards that have been used has been obtained from the eligible studies.

Yes: RT-PCR; confirmed or suspected case using official criteria (WHO, CDC) or a clearly set out combination of signs/symptoms/exposure 

Unclear: if it was unclear whether the results of the index test formed part of the reference standard.

High: if one or more signalling questions were answered with no.Low: if all signalling questions were answered with yes.

Is there concern that the target condition as defined by the reference standard does not match the review question?Applicability was judged primarily on the definition of disease-positive.High: if RT-PCR alone used to define cases Low: if clinical criteria, including RT-PCR, were used to define cases, regardless of whether official criteria were used, as long as the criteria were explicitly described.Unclear: if definition of COVID-19 cases was not provided, including if some clinically diagnosed cases were included but the clinical criteria used were not described.

Was there an appropriate interval between index test and reference standard? Reference: specimens with inconclusive results by a test, and those with discrepant results between index and the RT-PCR tests were analysed by a third RT-PCR method (see Table  3 ). 12 specimens (8 NPS, 4 NPS/OPS) were inconclusive and considered positive for data analysis purposes in the study. 1 NPS specimen was inconclusive by the Quest SARS-CoV-2 rRT-PCR test and negative by the Xpert test. This specimen was negative by a tie-breaker NAAT.

Index: presumptive positive results on index test were not reanalysed by the index test, but all discrepant results were reanalysed by a third RT-PCR method (Continued) Reference: re-testing of the FN and presumptive positive samples with RT-PCR (see Table 3 ); Index: 1 sample was positive only on N2 gene (considered negative according to IFU) and one was positive only on E gene (considered presumptive positive, requiring re-testing according to IFU Two or more groups -sensitivity and specificity 5 (2) 328 147

Single group -sensitivity and specificity 6 (6) 425 561Two or more groups -sensitivity and specificity 5 (7) 688 520 

JJD was the contact person with the editorial base.